Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre …
Background Both the safety and efficacy of biologic therapy may be affected in the presence
of highly prevalent chronic viral hepatitis. Objectives To evaluate the safety and …
of highly prevalent chronic viral hepatitis. Objectives To evaluate the safety and …
Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre …
R Navarro, E Vilarrasa, P Herranz, L Puig… - The British Journal of …, 2013 - europepmc.org
Background Both the safety and efficacy of biologic therapy may be affected in the presence
of highly prevalent chronic viral hepatitis. Objective To evaluate the safety and effectiveness …
of highly prevalent chronic viral hepatitis. Objective To evaluate the safety and effectiveness …
Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre …
R Navarro, E Vilarrasa, P Herranz… - The British journal …, 2013 - pubmed.ncbi.nlm.nih.gov
Background Both the safety and efficacy of biologic therapy may be affected in the presence
of highly prevalent chronic viral hepatitis. Objective To evaluate the safety and effectiveness …
of highly prevalent chronic viral hepatitis. Objective To evaluate the safety and effectiveness …
Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre …
R Navarro, E Vilarrasa, P Herranz, L Puig… - British Journal of …, 2013 - infona.pl
Background Both the safety and efficacy of biologic therapy may be affected in the presence
of highly prevalent chronic viral hepatitis. Objectives To evaluate the safety and …
of highly prevalent chronic viral hepatitis. Objectives To evaluate the safety and …
Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: A retrospective, multicentre …
R Navarro, E Vilarrasa, P Herranz… - British Journal of …, 2013 - portalrecerca.uab.cat
Background: Both the safety and efficacy of biologic therapy may be affected in the presence
of highly prevalent chronic viral hepatitis. Objectives To evaluate the safety and …
of highly prevalent chronic viral hepatitis. Objectives To evaluate the safety and …
[引用][C] Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective …
R NAVARRO, E VILARRASA… - British journal of …, 2013 - pascal-francis.inist.fr
Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients
with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a …
with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a …
Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre …
R Navarro, E Vilarrasa, P Herranz… - British Journal of …, 2013 - Wiley Online Library
Background Both the safety and efficacy of biologic therapy may be affected in the presence
of highly prevalent chronic viral hepatitis. Objectives To evaluate the safety and …
of highly prevalent chronic viral hepatitis. Objectives To evaluate the safety and …
Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre …
R Navarro, E Vilarrasa, P Herranz… - British Journal of …, 2013 - search.ebscohost.com
Background Both the safety and efficacy of biologic therapy may be affected in the presence
of highly prevalent chronic viral hepatitis. Objectives To evaluate the safety and …
of highly prevalent chronic viral hepatitis. Objectives To evaluate the safety and …
[引用][C] Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: A retrospective …
R Navarro, E Vilarrasa, P Herranz, L Puig… - British Journal of …, 2013 - portalciencia.ull.es
Background: Both the safety and efficacy of biologic therapy may be affected in the presence
of highly prevalent chronic viral hepatitis. Objectives To evaluate the safety and …
of highly prevalent chronic viral hepatitis. Objectives To evaluate the safety and …
Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre …
R Navarro, E Vilarrasa, P Herranz, L Puig, X Bordas… - 2013 - cabidigitallibrary.org
Background: Both the safety and efficacy of biologic therapy may be affected in the presence
of highly prevalent chronic viral hepatitis. Objectives: To evaluate the safety and …
of highly prevalent chronic viral hepatitis. Objectives: To evaluate the safety and …